Investigating the association between IL-6 antagonist therapy and blood coagulation in critically ill patients with COVID-19: a protocol for a prospective, observational, multicentre study.
Adult intensive & critical care
Bleeding disorders & coagulopathies
COVID-19
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
04 Nov 2022
04 Nov 2022
Historique:
entrez:
4
11
2022
pubmed:
5
11
2022
medline:
9
11
2022
Statut:
epublish
Résumé
Hypercoagulation is one the main features of COVID-19. It is induced by the hyperinflammatory response that shifts the balance of haemostasis towards pro-coagulation. Interleukin-6 (IL-6) antagonist therapy has been recommended in certain subgroups of critically ill patients with COVID-19 to modulate inflammatory response. The interaction between immune response and haemostasis is well recognised. Therefore, our objective is to evaluate whether the modulation of the inflammatory response by IL-6 antagonist inflicts any changes in whole blood coagulation as assessed by viscoelastic methods in critically ill patients with COVID-19. In this prospective observational study, we are going to collect data on inflammatory parameters and blood coagulation using the ClotPro Ethical approval was given by the Medical Research Council of Hungary (1405-3/2022/EÜG). All participants provided written consent. The results of the study will be disseminated through peer-reviewed journals. NCT05218369; Clinicaltrials.gov.
Identifiants
pubmed: 36332964
pii: bmjopen-2022-063856
doi: 10.1136/bmjopen-2022-063856
pmc: PMC9638747
doi:
Substances chimiques
Interleukin-6
0
Banques de données
ClinicalTrials.gov
['NCT05218369']
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e063856Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
Am J Cardiol. 2021 Mar 1;142:158-159
pubmed: 33417877
Int J Lab Hematol. 2021 Jul;43 Suppl 1:29-35
pubmed: 34288441
J Thromb Haemost. 2020 Jul;18(7):1743-1746
pubmed: 32320517
Br J Anaesth. 2021 Mar;126(3):590-598
pubmed: 33422287
J Proteome Res. 2020 Nov 6;19(11):4417-4427
pubmed: 32786691
Microb Pathog. 2021 Apr;153:104799
pubmed: 33609650
Lancet Respir Med. 2020 Jun;8(6):e46-e47
pubmed: 32353251
Bull World Health Organ. 2007 Nov;85(11):867-72
pubmed: 18038077
Clin Microbiol Infect. 2021 Feb;27(2):215-227
pubmed: 33161150
Nat Clin Pract Rheumatol. 2006 Nov;2(11):619-26
pubmed: 17075601
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
Curr Cardiol Rev. 2008 Aug;4(3):179-92
pubmed: 19936194
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Front Pharmacol. 2020 Jul 17;11:1093
pubmed: 32765283
Rheumatol Ther. 2018 Jun;5(1):21-42
pubmed: 29502236
Blood Adv. 2022 Sep 13;6(17):4915-4923
pubmed: 35503027
J Thorac Dis. 2017 Apr;9(Suppl 4):S299-S308
pubmed: 28540073
Can Geriatr J. 2020 Sep 01;23(3):210-215
pubmed: 32904824
Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):"677-686"
pubmed: 34519777
J Clin Med. 2021 Jan 07;10(2):
pubmed: 33430431
Pulmonology. 2021 Jan-Feb;27(1):52-66
pubmed: 32713784
Am J Emerg Med. 2021 May;43:27-30
pubmed: 33485124
J Clin Med. 2021 Apr 16;10(8):
pubmed: 33923851
Sci Rep. 2016 Aug 26;6:32188
pubmed: 27561337